Clinical advantages in providing artificial intelligence-assisted prostate cancer diagnosis: A pilot study
Pathology - Research and Practice · 2025
DOI: 10.1016/j.prp.2025.156007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2025. Verfasst von C Eloy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, Medical Faculty of University of Porto, Porto, Portugal; Pathology Laboratory, Institute of Molecular Pathology and Immunology …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Artificial Intelligence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate cancer is a prevalent male malignancy, with increasing incidence rates placing significant diagnostic burdens on pathology services worldwide. Artificial intelligence (AI) is emerging as a promising aid in enhancing diagnostic efficiency and accuracy. This study evaluates the clinical benefits of AI-assisted prostate biopsy (PB) diagnosis, with Paige Prostate tool, compared to non-AI-assisted PB diagnosis, focusing on its predictive accuracy for features in radical prostatectomy (RP) specimens. A retrospective analysis included 55 patients divided into two cohorts: one with non-AI-assisted PB diagnosis (n = 25) and another with AI-assisted PB diagnosis (n = 30). Pathological assessments recorded tumor size, Gleason score, Grade Group, and perineural invasion. The correlation between PB and RP results was analyzed, with statistical significance set at p < 0.05. AI-assisted PB diagnosis showed faster reporting times by 24 hours, enhancing workflow efficiency. AI assistance improved the correlation of tumor size between PB and RP, showing a substantial agreement (R=0.646, p < 0.001) compared to non-AI (R=0.479, p = 0.015). Gleason Score concordance increased by 13 % in the AI-assisted group, achieving 73.3 % versus 60 % in the non-AI-assisted group. This small pilot study suggests that AI-assisted PB diagnosis appears to enhance efficiency and accuracy in the diagnosis of prostate cancer, a finding to be confirmed with further studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pathology Department, Medical Faculty of University of Porto, Porto, Portugal; Pathology Laboratory, Institute of Molecular Pathology and Immunology of University of Porto (IPATIMUP), Porto, Portugal. Electronic address…
- 1st pathology department FSBI & National Medical Research Centre for Obstetrics, Gynecology and Perinatology Named after Academician V.I.Kulakov of the Ministry of Health of the Russian Federation, Moscow, Russia.
- Pathology Laboratory, Institute of Molecular Pathology and Immunology of University of Porto (IPATIMUP), Porto, Portugal.
- Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Greece.
- Urology Department, Hospital CUF Porto, Porto, Portugal.
- Pathology Laboratory, Institute of Molecular Pathology and Immunology of University of Porto (IPATIMUP), Porto, Portugal; Escola de Medicina e Ciências Biomédicas, Universidade Fernando Pessoa, Porto, Portugal.
Zitieren
APA
Eloy, C., Asaturova, A., Pinto, J., Rienda, I., Syrnioti, A., Prisco, R., & Polónia, A. (2025). Clinical advantages in providing artificial intelligence-assisted prostate cancer diagnosis: A pilot study. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.156007
Vancouver
Eloy C, Asaturova A, Pinto J, Rienda I, Syrnioti A, Prisco R, et al. Clinical advantages in providing artificial intelligence-assisted prostate cancer diagnosis: A pilot study. Pathology - Research and Practice. 2025. doi:10.1016/j.prp.2025.156007
BibTeX
@article{Eloy2025,
author = {Eloy, C and Asaturova, A and Pinto, J and Rienda, I and Syrnioti, A and Prisco, R and Polónia, A},
title = {Clinical advantages in providing artificial intelligence-assisted prostate cancer diagnosis: A pilot study},
journal = {Pathology - Research and Practice},
year = {2025},
doi = {10.1016/j.prp.2025.156007}
}
EUVIMED